According to the latest market report published by Credence Research, Inc. “Glaucoma Therapeutics Market – Growth, Future Prospects and Competitive Analysis, 2017 – 2025” the global Glaucoma Therapeutics market was valued at US$ 4.42 Bn in 2016, and is expected to reach US$ 5.67 Bn by 2025, expanding at a CAGR of 2.8% from 2017 to 2025.
The purpose of the report is to illustrate the state of the market of Glaucoma Therapeutics, to present actual information about the volumes of production, exports, imports, consumption and the state of the market, the changes that took place in 2017, and also, to build a forecast for the growth of the industry in the medium term until 2026.
Browse here for full report: https://www.credenceresearch.com/report/glaucoma-therapeutics-market
Market Insights
Glaucoma is chronic, degenerative disorder that damages the eye’s optic nerve that may result in vision loss and blindness. Glaucoma therapeutics is rapidly growing due to factors such as increase in prevalence of eye disorders around the world, significant unmet needs and rise in the incidence of age-related eye diseases contributing to the market growth of glaucoma therapeutics globally. For the purpose of study, global glaucoma therapeutics market is segmented on the basis of drug class such as prostaglandins analogs, beta blockers, alpha-adrenergic agonists, carbonic anhydrase inhibitors and fixed-dose combinations. It is observed that, in the base year 2016, prostaglandins analogs t was the highest contributing market segment. Prostaglandins analogs generally are given as first line therapy and higher adherence to the treatment are driving the market growth of prostaglandins analogs worldwide. Glaucoma therapeutics market is currently dominated by North America -. Factors such as higher cost of therapy and glaucoma being the second leading cause of blindness in the US are the factors driving the market growth in North America. Currently, Asia Pacific is not major revenue generating segment it is anticipated that Asia Pacific will show highest CAGR during forecast period. Factors such as increasing healthcare awareness, continuous economic development and developing healthcare infrastructure would drive the market growth during forecast period.
Market Competition Assessment:
The Glaucoma Therapeutics market is observed to be highly competitive and comprises large number of players. However, the market is currently dominated by few players such as Aerie Pharmaceuticals, Akorn, Inc., Allergan plc., Bausch & Lomb Incorporated, Inotek Pharmaceuticals, Merck & Co., Inc., Novartis AG, Pfizer Inc., Santen Pharmaceuticals Co. Ltd., Teva Pharmaceuticals and other.
Why was the report written?
This report is the result of an extensive survey drawn from Credence Research’s exclusive panel of leading global market industry executives; it provides data and analysis on buyer investment, acquisition, and developments within the global market research. It includes key topics such as global Glaucoma Therapeutics buyer expenditure and procurement behaviors and strategies and recognizes the threats and possibilities within the industry, economic outlook trends, and business confidence within global industry executives. Most secondary research reports are based on general industry drivers and do not understand the industry executives’ attitude and changing behaviors, creating a gap in presenting the business outlook of the industry; in an effort to bridge this gap, Credence Research created this primary research-based report by gathering the opinions of multiple stakeholders in the value chain of the global industry.
What is the current market landscape and what is changing?
Executives from the global industry anticipate an increase in levels of consolidation, with 55% of respondents projecting an increase in merger and acquisition (M&A) activities in 2017.
The report on the market of Glaucoma Therapeutics contains:
Analysis and forecast of Glaucoma Therapeutics market dynamics;
Analysis of domestic production, market shares of the main market players;
Analysis of exports and imports;
Analysis of factors, leading the development of the Glaucoma Therapeutics market;
Assessment and forecast of Glaucoma Therapeutics market development;
Financial and business profiles of the leading companies in the Glaucoma Therapeutics industry.
Scope
– Up to date working Glaucoma Therapeutics data by major regions in the world, the forecast of planned capacity additions by 2026
– The annual breakdown of capital expenditure spending on proposed Glaucoma Therapeutics for the period 2018 to 2026
– Planned Glaucoma Therapeutics additions and capital expenditure spending by key countries and companies across the world
– Planned capital expenditure spending on new Glaucoma Therapeutics projects by region, key countries, and companies
– Details of major planned Glaucoma Therapeutics projects in the world up to 2026
Also you can request us for sample in pdf with more details and graph: https://www.credenceresearch.com/sample-request/58436
About Us
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.
Contact Us:
Credence Research Inc.
105 N 1st ST #429
SAN JOSE
CA 95103
United States
Toll Free (US/CANADA): +1-800-361-8290